腫瘍病理鑑別診断アトラス　造血器腫瘍

出版社： 文光堂
著者：
発行日： 2013-05-29
分野： 臨床医学：基礎  >  臨床病理学
ISBN： 9784830622380
シリーズ： 腫瘍病理鑑別診断アトラス
電子書籍版： 2013-05-29 （第1版第2刷）
書籍・雑誌
≪全国送料無料でお届け≫
取寄せ目安：8～14営業日

16,500 円(税込)

購入する
電子書籍
章別単位での購入はできません
ブラウザ、アプリ閲覧

16,500 円(税込)

購入する

商品紹介

WHO分類第4版の組織分類に沿って，造血器腫瘍を組織学的視点から詳細に解説する．日常診療でよく遭遇する鑑別診断は，鑑別のポイントとして別項目にまとめ，病理医が知っておくべき造血器腫瘍の画像診断・治療方針に関しては，血液内科医にも記載して頂いた．血液内科医が病理診断に何を求めているかについては「病理診断報告書の記載」としてまとめた．さらに分類や概説では表せない必要事項を「トピックス」として盛り込んでいる．

目次

  • 腫瘍病理鑑別診断アトラス　造血器腫瘍

    ―目次―

    第１部　検鏡前の確認事項
    　?．骨髄評価のための基礎知識
    　II．成人の骨髄病理標本の評価
    　III．小児の骨髄と白血病の特徴

    第２部　組織型と診断の実際
    　?．骨髄増殖性腫瘍
    　II． 好酸球増加およびPDGFRA，PDGFRBまたはFGFR遺伝子異常を
    　　　　伴う骨髄系ならびにリンパ系腫瘍と慢性好酸球性白血病
    　III．骨髄異形成/骨髄増殖性腫瘍
    　IV．骨髄異形成症候群
    　?．小児骨髄異形成症候群
    　VI．急性骨髄性白血病と関連の前駆細胞腫瘍
    　VII．骨髄肉腫
    　VIII．Down症候群関連骨髄増殖性疾患
    　IX．芽球性形質細胞様樹状細胞腫瘍

    第３部　鑑別ポイント
    　?．芽球増加をきたす骨髄性腫瘍の鑑別
    　II．骨髄低形成をきたす骨髄性腫瘍の鑑別
    　III．骨髄線維化をきたす骨髄の鑑別
    　IV．巨核球の形態異常をきたす骨髄性腫瘍の鑑別
    　?．赤芽球増加をきたす骨髄性腫瘍の鑑別
    　VI．骨髄浸潤パターンからみた悪性リンパ腫の鑑別
    　VII．免疫組織化学による造血器腫瘍の鑑別

    第４部　臨床との連携
    　?．造血器腫瘍の画像診断
    　II．MDSにおけるリスク分類
    　III．急性骨髄性白血病におけるリスク分類
    　IV．造血器腫瘍における治療効果判定（分子標的治療を含む）
    　?．放射線障害と造血器腫瘍
    　VI．病理診断報告書の記載法

この書籍の参考文献

参考文献のリンクは、リンク先の都合等により正しく表示されない場合がありますので、あらかじめご了承下さい。

本参考文献は電子書籍掲載内容を元にしております。

第1部 検鏡前の確認事項

P.4 掲載の参考文献
1) 日本血液学会 (編) : 骨髄穿刺・骨髄生検. 血液専門医テキスト, 南江堂, 2011, pp47-49
 
2) 伊藤満 : 骨髄吸引と生検の適応と方法. 定平吉都 (編) : わかりやすい骨髄病理診断学, 西村書店, 2008, pp11-14
 
3) Bain BJ : Bone marrow trephine biopsy. J Clin Pathol 54 : 737-742, 2001
PubMed
P.16 掲載の参考文献
1) 巽典之, 土屋達行, 久保田勝英他 : 骨髄標本分析法-スクリーニング方法と考え方-, ベックマン・コールター (株), 2007, pp15-39
 
2) 巽典之, 土屋達行, 東克己他 : 見逃してはいけない骨髄スクリーニング所見と末梢血所見, ベックマン・コールター (株), 2008, pp13-37
 
3) 朝長万左男, 松田晃 (編) : 不応性貧血 (骨髄異形成症候群) の形態的学異型成に基づく診断確度区分と形態診断アトラス. 厚生労働科学研究費補助金難治性疾患克服研究事業 特発性造血障害に関する調査研究班, 2008, pp5-15
 
4) 小澤敬也 (編) : 特発性造血障害疾患の診療参照ガイド 平成22年度改訂版, 厚生労働科学研究費補助金 難治性疾患克服研究事業 特発性造血障害に関する調査研究班, 2011, pp61-98
 
5) Brunning RD, Orazi A, Germing U et al : Myelodysplastic syndromes. in Swerdlow SH, Campo E, Harris NL et al (eds) : "WHO Classification of Tumors of Haematopoietic and Lymphoid Tissues", IARC Press, Lyon, 2008, pp88-107
 
6) 渡辺明朗 : 普通染色 (ギムザ・ロマノウスキー染色) の基礎. 寺田秀夫 (監) : 血球カラーアトラス, 武藤化学, 2001, pp71-76
 
7) 亀井喜恵子 : 普通染色 (ギムザ・ロマノウスキー染色) の実際. 寺田秀夫 (監) : 血球カラーアトラス, 武藤化学, 2001, pp77-84
 
8) 大倉貢 : 骨髄塗抹標本と骨髄クロット・生検標本の比較. 定平吉都 (編) : 骨髄病理診断学, 西村書店, 2008, pp88-99
 
P.22 掲載の参考文献
1) Schaefer HE : How to fix, decalcify and stain paraffin embedded bone marrow biopsies. in Lennert K, Huebner K (eds) : "Pathology of the Bone Marrow", Fischer, Stuttgart 1984, pp33-53
 
2) 定平吉都, 小谷泰一, 小林博久 : 骨髄標本における特殊検査 (1) 特殊染色, 免疫染色. 病理と臨床 19 : 1071-1078, 2001
 
3) Leder LD : Ueber die selective fermentcytochemische Darstellung neutrophiler myeloischer Zellen und Gewebsmastzellen am Paraffinschnitt. Klin Wochenschr 42 : 553, 1964
 
4) 伊藤雅文 : 骨髄. 外科病理マニュアル, 病理と臨床 26 (臨増) : 261-266, 2008
 
P.33 掲載の参考文献
1) Jaffe ES, Harris NL, Stein H et al (eds) : WHO Classification of Tumors. Pathology & Genetics. Tumours of Haematopoietic and Lymphoid Tissues. IARC Press, Lyon, 2008
 
2) Schanz J, Tuchler H, Sole F et al : New comprehensive cytogenetic scoring system for primary myelodysplastic syndromes (MDS) and oligoblastic acute myeloid leukemia after MDS derived from an international database merge. J Clin Oncol 30 : 820-829, 2012
PubMed
3) Malcovati L, Germing U, Kuendgen A et al : Time-dependent prognostic scoring system for predicting survival and leukemic evolution in myelodysplastic syndromes. J Clin Oncol 25 : 3503-3510, 2007
PubMed
4) Sandberg Y, van Gastel-Mol EJ, Verhaaf B et al : BIOMED-2 multiplex immunoglobulin/T-cell receptor polymerase chain reaction protocols can reliably replace Southern blot analysis in routine clonality diagnostics. J Mol Diagn 7 : 495-503, 2005
PubMed
5) Baccarani M, Saglio G, Goldman J et al : Evolving concepts in the management of chronic myeloid leukemia : recommendations from an expert panel on behalf of the European LeukemiaNet. Blood 108 : 1809-1820, 2006
 
6) Cleary ML, Chao J, Warnke R et al : Immunoglobulin gene rearrangement as a diagnostic criterion of B-cell lymphoma. Proc Natl Acad Sci USA 81 : 593-597, 1984
PubMed
7) Langerak AW, Wolvers-Tettero IL, van Dongen JJ : Detection of T cell receptor beta (TCRB) gene rearrangement patterns in T cell malignancies by Southern blot analysis. Leukemia 13 : 965-974, 1999
 
P.44 掲載の参考文献
1) Vardiman JW, Porwit A, Brunning RD et al : Introduction and over view of the classification of the myeloid neoplasms. in Swerdlow SH, Campo E, Harris NL, et al (eds) : "WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues". IARC Press, Lyon, 2008, pp18-30
 
2) 定平吉都 : 骨髄組織標本の見方 (1). 定平吉都 (編) : わかりやすい骨髄病理診断学-吸引クロット/生検組織の見方-. 西村書店, 2008, pp48-63
 
3) 定平吉都 : 骨髄異形成症候群における骨髄標本の鉄染色-経口鉄キレート剤の適用判定における鉄沈着のgrading-. 病理と臨床 27 : 686-687, 2009
Medical*Online
4) Lundin P, Persson E, Weinfeld A : Comparison of hemosiderin estimation in bone marrow sections and bone marrow smears. Acta Med Scand 175 : 383-390, 1964
PubMed
5) 定平吉都 : 赤芽球島. 病理形態学キーワード, 病理と臨床 28 (臨増) : 344-345, 2010
 
6) Visconte V, Rogers HJ, Singh J et al : SF3B1 haploinsufficiency leads to formation of ring sideroblasts in myelodysplastic syndromes. Blood 120 : 3173-3186, 2012
PubMed
P.49 掲載の参考文献
1) Foucar K, Viswanatha DS, Wilson CS : Non-neoplastic Disorders of Bone Marrow. ARP Press, Washington, 2008, pp1-40
 
2) McKenna RW, Washington LT, Aquino DB et al. : Immunophenotypic analysis of hematogones (B-lymphocyte precursors) in 662 consecutive bone marrow specimens by 4-color flow cytometry. Blood 98 : 2498-2507, 2001
PubMed
3) 宮内潤, 泉二登志子 (編) : 骨髄疾患診断アトラス : 血球形態と骨髄病理. 中外医学社, 2010
 
4) 川口裕之, 宮内潤 : 小児のMDS : その特徴と診断上の注意点. 病理と臨床 30 : 848-855, 2012
Medical*Online
5) Ford AM, Ridge SA, Cabrera ME et al : In utero rearrangements in the trithorax-related oncogene in infant leukaemias. Nature 363 : 358-360, 1993
PubMed
6) Gale KB, Ford AM, Repp R et al : Backtracking leukemia to birth ; identification of clonotypic gene fusion sequences in neonatal blood spots. Proc Natl Acad Sci USA 94 : 13950-13954, 1997
PubMed
7) Ford AM, Bennet CA, Price CM et al : Fetal origins of the TEL-AML1 fusion gene in identical twins with leukemia. Proc Natl Acad Sci USA 95 : 4584-4588, 1998
 
8) Wiemels JL, Ford AM, van Wering ER et al : Protracted and variable latency of acute lymphoblastic leukemia after TEL-AML1 gene fusion in utero. Blood 94 : 1057-1062. 1999
PubMed
9) Seif AE : Pediatric leukemia predisposition syndromes : clues to understanding leukemogenesis. Cancer Genet 204 : 227-244, 2011
PubMed

第2部 組織型と診断の実際

P.57 掲載の参考文献
1) Braziel RM, Launder TM, Druker BJ et al : Hematopathologic and cytogenetic findings in imatinib mesylate-treated chronic myelogenous leukemia patients : 14 months' experience. Blood 100 : 435-441, 2002
PubMed
2) Hasserjian RP, Boeklin F, Parker S et al : STI571 (imatinib mesylate) reduces bone marrow cellularity and normalizes morphologic features irrespective of cytogenetic response. Am J Clin Pathol 117 : 360-367, 2002
 
3) Beham-Schmid C, Apfelbeck U, Sill H et al : Treatment of chronic myelogenous leukemia with the tyrosine kinase inhibitor STI571 results in marked regression of bone marrow fibrosis. Blood 99 : 381-383, 2002
PubMed
4) Frater JL, Tallman MS, Variakojis D et al : Chronic myeloid leukemia following therapy with imatinib mesylate (Gleevec). Am J Clin Hematol 119 : 833-841, 2003
 
5) Goldman JM, Melo JV : Targeting the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N Engl J Med 344 : 1084-1086, 2001
PubMed
P.62 掲載の参考文献
1) Swerdlow SH, Campo E, Harris NL et al (eds) : WHO Classification of Tumours of Haematopietic and Lymphoid Tissue, 4th ed, IARC Press, Lyon, 2008
 
2) 近藤敏範, 定平吉都, 杉原尚 : 骨髄増殖性腫瘍とJAK2遺伝子変異. 病理と臨床 27 : 1059-1065, 2009
Medical*Online
3) 桐戸啓太 : 骨髄増殖性腫瘍と類縁疾患. 臨床血液 50 : 134-146, 2009
 
4) 定平吉都 : わかりやすい骨髄病理診断学 吸引クロット, 生検組織の見方, 西村書店, 2008
 
5) 秋山隆, 定平吉都 : 各臓器, 疾患で用いられる抗体とその応用 骨髄. 診断に役立つ免疫組織化学, 病理と臨床 25 (臨増) : 169-176, 2007
 
6) 岩地道伸久, 小林博久, 定平吉都 : 私のこだわり・工夫 骨髄病理標本の固定にはブアン液が最適である. 外科病理マニュアル, 病理と臨床 26 (臨増) : 395-397, 2008
 
P.69 掲載の参考文献
1) Thiele J, Kvansnicka HM, Tefferi A et al : Primary myelofibrosis. in Swerdlow SH, Campo E, Harris NL et al (eds) : "WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues", 4th ed). IARC Press, Lyon, 2008, pp44-47
 
2) 骨髄線維症の診断基準と診療の参照ガイド作成のためのワーキンググループ : 骨髄線維症の診療の参照ガイド, 平成22年度改訂版. 小澤敬也 (編) : 特発性造血障害疾患の診療の参照ガイド, 平成22年度改訂版, 厚生労働科学研究費補助金難治性疾患克服研究事業 特発性造血障害に関する調査研究班. 2011, pp177-202
 
3) Agool A, Glaudemans AW, Boersma HH et al : Radionuclide imaging of bone marrow disorders. Eur J Nucl Med Mol Imaging 38 : 166-178, 2011
PubMed
4) Le Bousse-Kerdiles MC, MArtyre MC, Samson M : Cellular and molecular mechanisms underlying bone marrow and liver fibrosis : a review. Eur Cytokine Netw 19 : 69-80, 2008
 
5) Thiele J, Kvasnicka HM, Facchetti F et al : European consensus on grading bone marrow fibrosis and assessment of cellularity. Haematologica 90 : 1128-1132, 2005
PubMed
6) Gianelli U, Vener C, Bossi A, et al : The European Consensus on grading of bone marrow fibrosis allows a better prognostication of patients with primary myelofibrosis. Mod Pathol 25 : 1193-1202, 2012
PubMed
7) DeLario MR, Sheehan AM, Ataya R et al : Clinical, histopathologic, and genetic features of pediatric primary myelofibrosis-an entity different from adults. Am J Hematol 87 : 461-464, 2012
PubMed
8) Schnittger S, Bacher U, Eder C et al : Molecular analyses of 15,542 patients with suspected BCR-ABL1-negative myeloproliferative disorders allow to develop a stepwise diagnostic workflow. Haematologica 97 : 1582-1585, 2012
PubMed
9) Terreri A : Primary myelofibrosis : 2012 update on diagnosis, risk stratification, and management. Am J Hematol 86 : 1018-1026, 2011
 
10) Tefferi A : Myeloproliferative neoplasms 2012 : The John Bennett 80th birthday anniversary lecture. Leuk Res 36 : 1481-1489, 2012
 
P.73 掲載の参考文献
1) Swerdlow SH, Campo E, Harris NL et al (eds) : WHO Classification of Tumours of Haematopietic and Lymphoid Tissue, 4th ed, IARC Press, Lyon, 2008
 
2) Campbell PJ, Scott LM, Buck G et al : Definition of subtypes of essential thrombocythaemia and relation to polycythaemia vera based on JAK2 V617F mutation status : a prospective study. Lancet 366 : 1945-1953, 2005
PubMed
3) 近藤敏範, 定平吉都, 杉原尚 : 骨髄増殖性腫瘍とJAK2遺伝子変異. 病理と臨床 27 : 1059-1065, 2009
Medical*Online
4) 定平吉都 : わかりやすい骨髄病理診断学 吸引クロット, 生検組織の見方, 西村書店, 2008
 
5) 秋山隆, 定平吉都 : 各臓器, 疾患で用いられる抗体とその応用 骨髄. 診断に役立つ免疫組織化学, 病理と臨床 25 (臨増) : 169-176, 2007
 
P.78 掲載の参考文献
1) 西山千春 : マスト細胞の分化 (幹細胞から). アレルギー・免疫 13 : 796-802, 2006
 
2) Horny HP, Metcalfe DD, Bennett JM et al : Mastocytosis. in : Swerdlow SH, Campo E, Harris NL, et al (eds) : "WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues", IARC Press, Lyon, 2008, pp54-63
 
3) Farhi DC : Pathology of Bone Marrow and Blood Cells, 2nd ed., Lippincott Wiliams & Wilkins, Boltimore, 2009
 
4) 塩沢英輔, 本間まゆみ, 瀧本雅文他 : 血液・骨髄 肥満細胞. 病理形態学キーワード, 病理と臨床 28 (臨増) : 336-337, 2010
 
5) Lim KH, Tefferi A, Lasho TL et al : Systemic mastocytosis in 342 consecutive adults : survival studies and prognostic factors. Blood 113 : 5727-5236, 2009
PubMed
6) Naeim F : Pathology of Bone Marrow, 2nd ed, Wiliams & Wilkins, Boltimore, 1998
 
7) 水木満佐央, 金倉譲 : 肥満細胞症の病因・病態と治療. 造血器腫瘍学-基礎と臨床の最新研究動向-, 日本臨牀 70 (増刊) : 337-341, 2012
 
8) Tefferi A, Levine RL, Lim KH et al : Frequent TET2 mutations in systemic mastocytosis : clinical, KITD816V and FIP1L1-PDGFRA correlates. Leukemia 23 : 900-904, 2009
PubMed
9) Wilson TM, Maric I, Simakova O et al : Clonal analysis of NRAS activating mutations in KIT-D816V systemic mastocytosis. Haematologica 96 : 459-463, 2011
PubMed
10) 今井利, 盛實篤史, 中村知志保他 : 肥満細胞性白血病の一例. 高知医療センター医学雑誌 3 : 25-31, 2009
 
P.84 掲載の参考文献
1) Chusid MJ, Dale DC, West BC et al : The hypereosinophilic syndrome : analysis of fourteen cases with review of the literature. Medicine 54 : 1-27, 1975
PubMed
2) Bain B, Pierre R, Imbert M et al : Chronic eosinophilic leukaemia and the hypereosinophilic syndrome. in Jaffe ES, Harris NL, Stein H et al (eds) : "WHO Classification of Tumours. Pathology & Genetics. Tumours of Haematopoietic and Lymphoid Tissues", IARC Press, Lyon, 2001, pp29-31
 
3) Cools J, DeAngelo DJ, Gotlib J et al : A tyrosine kinase created by the fusion of the PDGFRA and FIP1L1 genes as a therapeutic target of imatinib in idiopathic hypereosinophilic syndrome. New Engl J Med 348 : 1201-1214, 2003
PubMed
4) Bain BJ, Gilliland DG, Horny HP et al : Myeloid and lymphoid neoplasms with eosinophilia and abnormalities of PDGFRA, PDGFRB or FGR. in Jaffe ES, Harris NL, Stein H et al (eds) : "WHO Classification of Tumours. Pathology & Genetics. Tumours of Haematopoietic and Lymphoid Tissues", IARC Press, Lyon, 2008, pp68-73
 
5) Bain BJ, Gilliland DG, Vardiman JW et al : Chronic eosinophilic leukaemia, not otherwise specified. in Jaffe ES, Harris NL, Stein H et al (eds) : "WHO Classification of Tumours. Pathology & Genetics. Tumours of Haematopoietic and Lymphoid Tissues", IARC Press, Lyon, 2008, pp51-53
 
6) Crane MM, Chang CM, Kobayashi MG et al : Incidence of myeloproliferative hypereosinophilic syndrome in the United States and an estimate of all hypereosinophilic syndrome incidence. J Allergy Clin Immunol 126 : 179-181, 2010
 
7) 定明子, 松井俊充 : 本邦における慢性好酸球性白血病/特発性好酸球増多症候群の臨床像と治療. 臨床血液 51 : 515-525, 2010
 
8) Klion AD, Noel P, Akin C et al : Elevated serum tryptase levels identify a subset of patients with a myeloproliferative variant of idiopathic hypereosinophilic syndrome associated with tissue fibrosis, poor prognosis, and imatinib responsiveness. Blood 101 : 4660-4666, 2003
PubMed
9) Klion AD, Robyn J, Akin C et al : Molecular remission and reversal of myelofibrosis in response to imatinib mesylate treatment in patients with the myeloproliferative variant of hypereosinophilic syndrome. Blood 103 : 473-478, 2004
PubMed
10) Gotlib J, Cross NC, Gilliland DG : Eosinophilic disorders : molecular pathogenesis, new classification, and modern therapy. Best Pract Res Clin Haematol 19 : 535-569, 2006
 
11) Jackson CC, Medeiros LJ, Miranda RN : 8p11 myeloproliferative syndrome : a review. Hum Pathol 41 : 461-476, 2010
PubMed
P.95 掲載の参考文献
1) Orazi A, Bennet JM, Germing U et al : Myelodysplastic/myeloproliferative neplasms. in Swerdlow SH, Campo E, Harris NL et al (eds) : "WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues", IARC Press, Lyon, 2008, pp76-86
 
2) Hall J, Foucar K : Diagnosing myelodysplastic/myeloproliferative neoplasms : laboratory testing strategies to exclude other disorders. Int J Lab Hematol 32 : 559-571, 2010
PubMed
3) Germing U, Strupp C, Knipp S et al : Chronic myelomonocytic leukemia in the light of the WHO proposals. Haematologica 92 : 974-977, 2007
PubMed
4) Orazi A, Germing U : The myelodysplastic/myeloproliferative neoplasms : myeloproliferative diseases with dysplastic features. Leukemia 22 : 1308-1319, 2008
PubMed
5) Naresh KN : Morphological evaluation of monocytes and monocyte precursors in bone marrow trephine biopsies-need for establishing diagnostic criteria. Haematologica 94 : 994-997, 2009
 
6) Orazi A, Chiu R, O'Malley DP et al : Chronic myelomonocytic leukemia : The role of bone marrow biopsy immunohistology. Mod Pathol 19 : 1536-1545, 2006
 
7) Koike K, Matsuda K : Recent advances in the pathogenesis and management of juvenile myelomonocytic leukaemia. Br J Haematol 141 : 567-575, 2008
PubMed
8) Flotho C, Kratz C, Niemeyer CM : Targeting RAS signaling pathways in juvenile myelomonocytic leukemia. Curr Drug Targets 8 : 715-725, 2007
PubMed
9) Breccia M, Biondo F, Latagliata R et al : Identification of risk factors in atypical chronic myeloid leukemia. Haematologica 91 : 1566-1568, 2006
PubMed
10) Xubo G, Xingguo L, Xianguo W et al : The role of peripheral blood, bone marrow aspirate and especially bone marrow trephine biopsy in distinguishing atypical chronic myeloid leukemia from chronic granulocytic leukemia and chronic myelomonocytic leukemia. Eur J Haematol 83 : 292-301, 2009
PubMed
11) McClure RF, Dewald GW, Hoyer JD et al : Isolated isochromosome 17q : a distinct type of mixed myeloproliferative disorder/myelodysplastic syndrome with an aggressive clinical course. Br J Haematol 106 : 445-454, 1999
PubMed
12) Broseus J, Florensa L, Zipperer E et al : Clinical features and course of refractory anemia with ring sideroblasts associated with marked thrombocytosis. Haematologica 97 : 1036-1041, 2012
PubMed
13) Szpurka H, Tiu R, Murugesan G et al : Refractory anemia with ringed sideroblasts associated with marked thrombocytosis (RARS-T), another myeloproliferative condition characterized by JAK2 V617F mutation. Blood 108 : 2173-2181, 2006
PubMed
14) Nearman ZP, Szpurka H, Serio B et al : Hemochromatosisassociated gene mutations in patients with myelodysplastic syndromes with refractory anemia with ringed sideroblasts. Am J Hematol 82 : 1076-1079, 2007
PubMed
P.125 掲載の参考文献
1) Bennett JM, Catovsky D, Daniel MT et al : Proposed revised criteria for the classification of acute myeloid leukemia. A report of the French-American-British Cooperative Group. Ann Intern Med 103 : 620-625, 1985
PubMed
2) Jaffe ES, Harris NL, Stein H et al (eds) : WHO Classification of Tumour of Haematopoietic and Lymphoid Tissues, IARC Press, Lyon, 2001
 
3) Swerdlow SH, Campo E, Harris NL et al (eds) : WHO Classification of Tumour of Haematopoietic and Lymphoid Tissues, IARC Press, Lyon, 2008
 
4) Kitagawa M, Kurata M, Yamamoto K et al : Molecular pathology of myelodysplastic syndromes : biology of medullary stromal and hematopoietic cells (review). Mol Med Report 4 : 591-596, 2011
 
5) Choi JW, Fujino M, Ito M : F-blast is a useful marker for differentiating hypocellular refractory anemia from aplastic anemia. Int J Hematol 75 : 257-260, 2002
 
6) Kitagawa M, Yoshida S, Kuwata T et al : p53 expression in myeloid cells of myelodysplastic syndromes. Association with evolution of overt leukemia. Am J Pathol 145 : 338-344, 1994
PubMed
7) Ebert BL, Pretz J, Bosco J et al : Identification of RPS14 as a 5q-syndrome gene by RNA interference screen. Nature 451 : 335-339, 2008
PubMed
8) Yoshida K, Sanada M, Shiraishi Y et al : Frequent pathway mutations of splicing machinery in myelodysplasia. Nature 478 : 64-69, 2011
PubMed
9) Malcovati L, Porta MG, Pascutto C et al : Prognostic factors and life expectancy in myelodysplastic syndromes classified according to WHO criteria : a basis for clinical decision making. J Clin Oncol 23 : 7594-7603, 2005
PubMed
10) Neukirchen J, Fox F, Kundgen A et al : Improved survival in MDS patients receiving iron chelation therapy-a matched pair analysis of 188 patients from the Dusseldorf MDS registry. Leuk Res 36 : 1067-1070, 2012
PubMed
11) Kitagawa M, Kurata M, Yamamoto K et al : Molecular pathology of myelodysplastic syndromes : biology of medullary stromal and hematopoietic cells (review). Mol Med Report 4 : 591-596, 2011
 
12) Ding L, Saunders TL, Enikolopov G et al : Endothelial and perivascular cells maintain haematopoietic stem cells. Nature 481 : 457-462, 2012
PubMed
13) Sugiyama T, Nagasawa T : Bone marrow niches for hematopoietic stem cells and immune cells. Inflamm Allergy Drug Targets 11 : 201-206, 2012
PubMed
14) Yamazaki S, Ema H, Karlsson G et al : Nonmyelinating Schwann cells maintain hematopoietic stem cell hibernation in the bone marrow niche. Cell 147 : 1146-1158, 2011
PubMed
15) Raaijmakers MH, Mukherjee S, Guo S et al : Bone progenitor dysfunction induces myelodysplasia and secondary leukaemia. Nature 464 : 852-857, 2010
PubMed
16) Valent P, Horny HP, Bennett JM et al : Definitions and standards in the diagnosis and treatment of the myelodysplastic syndromes : Consensus statements and report from a working conference. Leuk Res 31 : 727-736, 2007
PubMed
17) Valent P, Horny HP : Minimal diagnostic criteria for myelodysplastic syndromes and separation from ICUS and IDUS : update and open questions. Eur J Clin Invest 39 : 548-553, 2009
PubMed
18) Valent P, Bain BJ, Bennett JM et al : Idiopathic cytopenia of undetermined significance (ICUS) and idiopathic dysplasia of uncertain significance (IDUS), and their distinction from low risk MDS. Leuk Res 36 : 1-5, 2012
PubMed
P.133 掲載の参考文献
1) Baumann I, Niemeyer CM, Benett JM et al : Childhood myelodysplastic syndrome. in Swerdlow SH, Campo E, Harris NL et al (eds) : "WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues", 4th ed, IARC Press, Lyon, 2008, pp104-107
 
2) 濱麻人, 伊藤雅文 : MDS骨髄病理診断の標準化. 病理と臨床 30 : 832-839, 2012
Medical*Online
3) Tischkowitz M, Dokal I : Fanconi anemia and leukemia : clinical and molecular aspects. Br J Hematol 126 : 176-191, 2004
 
4) Alter BP, Baerlocher GM, Savage SA et al : Very short telomere length by flow fluorescence in situ hybridization identifies patients with dyskeratosis congenita. Blood 110 : 1439-1447, 2007
PubMed
5) Sieff CA, Yang J, Merida-Long LB et al : Pathogenesis of the erythroid failure in Diamond Blackfan anaemia. Br J Hematol 148 : 611-622, 2010
 
6) Wickramasinghe SN, Wood WG : Advances in the understanding of the congenital dyserythropoietic anaemias. Br J Hematol 131 : 431-446, 2005
 
7) Boocock GR, Morrison JA, Popovic M et al : Mutations in SBDS are associated with Shwachman-Diamond syndrome. Nat Genet 33 : 97-101, 2003
PubMed
8) Bellanne-Chantelot C, Clauin S, Leblanc T et al : Mutations in the ELA2 gene correlate with more severe expression of neutropenia : a study of 81 patients from the French Neutropenia Register. Blood 103 : 4119-4125, 2004
PubMed
9) 伊藤雅文, 市橋亮一, 岩淵英人 : ITPと脾臓. 病理と臨床 22 : 1272-1275, 2004
Medical*Online
10) 朝長万左男, 松田晃 : 不応性貧血 (骨髄異形成症候群) の形態学的異形成に基づく診断確度区分と形態診断アトラス. 厚生労働科学研究費補助金, 難治性疾患克服研究事業, 特発性造血障害に関する調査研究班報告書 (平成19年度)
 
11) Choi JW, Fujino M, Ito M : F-blast is a useful marker for differentiating hypocellular refractory anemia from aplastic anemia. Int J Hematol 75 : 257-260, 2002
 
12) Choi JW, Kim Y, Fujino M et al : Significance of fetal hemoglobin-containing erythroblasts (F blasts) and the F blast/F cell ratio in myelodysplastic syndromes. Leukemia 16 : 1478-1483, 2002
 
13) Iwasaki T, Murakami M, Sugisaki C et al : Characterization of myelodysplastic syndrome and aplastic anemia by immunostaining of p53 and hemoglobin F and karyotype analysis : differential diagnosis between refractory anemia and aplastic anemia. Pathol Int 58 : 353-360, 2008
PubMed
P.147 掲載の参考文献
1) Bennett JM, Catovsky D, Daniel MT et al : Proposed revised criteria for the classification of acute myeloid leukemia. A report of the French-American-British Cooperative Group. Ann Intern Med 103 : 620-625, 1985
PubMed
2) Jaffe ES, Harris NL, Stein H et al (eds) : WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues, IARC Press, Lyon, 2001
 
3) Swerdlow SH, Campo E, Harris NL et al (eds) : WHO Classification of Tumour of Haematopoietic and Lymphoid Tissues, IARC Press, Lyon, 2008
 
4) Kelly LM, Gilliland DG : Genetics of myeloid leukemias. Annu Rev Genomics Hum Genet 3 : 179-198, 2002
PubMed
5) Ageberg M, Drott K, Olofsson T et al : Identification of a novel and myeloid specific role of the leukemia-associated fusion protein DEK-NUP214 leading to increased protein synthesis. Genes Chromosomes Cancer 47 : 276-287, 2008
PubMed
6) Gilliland DG, Griffin JD : The roles of FLT3 in hematopoiesis and leukemia. Blood 100 : 1532-1542, 2002
PubMed
7) Grundler R, Miething C, Thiede C et al : FLT3-ITD and tyrosine kinase domain mutants induce 2 distinct phenotypes in a murine bone marrow transplantation model. Blood 105 : 4792-4799, 2005
 
8) Yoshimoto G, Miyamoto T, Jabbarzadeh-Tabrizi S et al : FLT3-ITD up-regulates MCL-1 to promote survival of stem cells in acute myeloid leukemia via FLT3-ITD-specific STAT5 activation. Blood 114 : 5034-5043, 2009
PubMed
9) Kikushige Y, Akashi K : TIM-3 as a therapeutic target for malignant stem cells in acute myelogenous leukemia. Ann NY Acad Sci 1266 : 118-123, 2012
PubMed
10) Martinelli G, Ottaviani E, Buonamici S et al : Association of 3q21q26 syndrome with different RPN1/EVI1 fusion transcripts. Haematologica 88 : 1221-1228, 2003
PubMed
11) Descot A, Rex-Haffner M, Courtois G et al : OTT-MAL is a deregulated activator of serum response factor-dependent gene expression. Mol Cell Biol 28 : 6171-6181, 2008
PubMed
12) Schlenk RF, Dohner K : Impact of new prognostic markers in treatment decisions in acute myeloid leukemia. Curr Opin Hematol 16 : 98-104, 2009
PubMed
13) Marcucci G, Haferlach T, Dohner H : Molecular genetics of adult acute myeloid leukemia : prognostic and therapeutic implications. J Clin Oncol 29 : 475-486, 2011
PubMed
P.154 掲載の参考文献
1) Brito-Babapulle F, Catovsky D, Galton DA : Clinical and laboratory features of de novo acute myeloid leukemia with trilineage myelodysplasia. Br J Haematol 66 : 445-450, 1987
PubMed
2) Jaffe ES, Harris NL, Stein H et al (eds) : WHO Classification of Tumours. Pathology & Genetics. Tumours of Haematopoietic and Lymphoid Tissue, IARC Press, Lyon, 2001
 
3) Swerdlow SH, Campo E, Harris NL et al (eds) : WHO Classification of Tumours of Haematopoietic and Lymphoid Tissue, IARC Press, Lyon, 2008
 
4) 宮内潤, 泉二登志子 (編) : 骨髄疾患診断アトラス-血球形態と骨髄病理-, 中外医学社, 2012, pp174-176
 
5) 栗山一孝 : 多血球系に異形成を認めるAML. 阿部達夫 (編) : 造血器腫瘍アトラス-形態, 免疫, 染色体と遺伝子, 日本医事新報社, 2009, pp263-267
 
6) 宮崎泰司 : 骨髄異形成に関連した変化を有するAML. 木崎昌弘, 田丸淳一 (編) : WHO分類第4版による白血病・リンパ系腫瘍の病態学, 中外医学社, 2009, pp125-128
 
7) Miyazaki Y, Kuriyama K, Miyawaki S et al : Cytogenetic heterogeneity of acute myeloid leukaemia (AML) with trilineage dysplasia : Japan Adult Leukaemia Study Group-AML 92 Study. Br J Haematol 120 : 56-62, 2003
 
8) Weinberg OK, Seetharam M, Ren L et al : Arber clinical characterization of acute myeloid leukemia with myelodysplasia-related changes as defined by the 2008 WHO classification system. Blood 113 : 1906-1908, 2009
PubMed
P.158 掲載の参考文献
1) Mauritson N, Albibn M, Rylander L et al : Pooled analysis pf clinical and cytogenetic features in treatment-related and de novo adult acute myeloid leukemia and myelodysplastic syndromes based on a consecutive series of 761 patients analyzed 1976-1993 and on 5098 unselected cases reported literature 1974-2001. Leukemia 16 : 2366-2378, 2002
 
2) Smith SM, Le Beau MM, Huo D et al : Clinical cytogenetic associations in 306 patients with therapy-related myelodysplasia and myeloid leukemia. The university of Chicago series. Blood 102 : 43-52, 2003
PubMed
3) Michels SD, Mckenna RW, Arthur DC et al : Therapy-related acute myeloid leukemia and myelodysplastic syndrome : a clinical and morphologic study of 65 cases. Blood 65 : 1364-1372, 1985
PubMed
4) Singh ZN, Huo D, Anasyasi J et al : Therapy-related myelodysplastic syndrome : morphologic subclassification may not be clinically relevant. Am J Cli Pathol 127 : 197-205, 2007
PubMed
5) Anderson MK, Larson RA, Mauritzson N et al : Balanced chromosome abnormalities inv (16) and t (15 ; 17) in therapy-related myelodysplastic syndrome and acute leukemia : report from an international work shop. Genes Chromosomes Cancer 33 : 395-400, 2002
 
6) Rowley JD, Olney HJ : International workshop on the relationship of prior therapy to balanced chromosome aberrations in therapy-related myelodysplastic syndrome and acute leukemia : overview report. Gene Chromosomes Cancer 33 : 331-345, 2002
PubMed
7) Slovac ML, Bedell V, Popplewell L et al : 21q22 balanced chromosome aberrations in therapy-related hematopietic disorders : report from an international workshop. Gene Chromosomes Cancer 33 : 379-394, 2002
 
8) Ishizawa S, Slovak ML, Popplewell L et al : High frequency of pro-B acute lymphoblastic leukemia in adults with secondary leukemia with 11q23 abnormalities. Leukemia 17 : 1091-1095, 2003
 
P.174 掲載の参考文献
1) Arber DA, Brunning RD, Orazi A et al : Acute myeloid leukaemia, not otherwise specified. in Swerdlow SH, Campo E, Harris NL et al (eds) : "WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues", 4th ed, IARC Press, Lyon, 2008, pp130-139
 
2) Bain BJ : Leukaemia Diagnosis, 4th ed, Wiley Blackwell, West Sussex, 2010, p160
 
3) Bennett JM, Catovsky D, Daniel MT et al : Proposal for the classification of acute leukaemias. French-American-British (FAB) co-operative group. Br J Haematol 33 : 451-458, 1976
PubMed
4) Bennett JM, Catovsky D, Daniel MT et al : Criteria for the diagnosis of acute leukaemia of megakaryocytic lineage (M7) : a report of the French-American-British cooporative group. Ann Int Med 103 : 460-462, 1985
 
5) Bennett JM, Catovsky D, Daniel MT et al : Proposal for the recognition of minimally differentiated acute myeloid leukaemia (AML M0). Br J Haematol 78 : 325-329, 1991
 
6) Doll DC, List AF : Myelodysplastic syndromes : introduction. Semin Oncol 19 : 1-3, 1992
 
7) Bennett JM, Catovsky D, Daniel MT et al : Proposals for the classification of the myelodysplastic syndromes. Br J Haematol 51 : 189-199, 1982
PubMed
8) Bain BJ : Leukaemia Diagnosis, 4th ed, Wiley Blackwell, West Sussex, 2010, p219
 
9) Hamblin TJ : Epidermiology of the myelodysplastic syndromes. in Bennett JM (ed) : "The Myelodysplastic Syndromes : Patholgy and Clinical Management", Marcel Dekker, New York, 200, pp15-28
 
10) Vardiman JW, Brunning RD, Arber DA et al : Introduction and over view of the classification of the myeloid neoplasms. in Swerdlow SH, Campo E, Harris NL et al (eds) : "WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues", 4th ed, IARC Press, Lyon, 2008, pp18-23
 
11) Brunning RD, Orazi A, Germing U et al : Myelodysplastic syndromes/neoplasms, overview. in Swerdlow SH, Campo E, Harris NL et al (eds) : "WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues", 4th ed, IARC Press, Lyon, 2008, pp88-93
 
12) Bain BJ : Leukaemia Diagnosis, 4th ed, Wiley Blackwell, West Sussex, 2010, pp6-7
 
13) Goasguen JE, Bennett JM, Cox C et al : Prognostic implication and characterization of the blast cell population in the myelodysplastic syndrome. Leuk Res 15 : 1159-1165, 1991
PubMed
14) Mufti GJ, Bennett JM, Goasguen J et al : Diagnosis and classification of MDS : International Working Group on Morphology of MDS (IWGM-MDS) consensus proposals for the definition and enumeration of myeloblasts and ring sideroblasts. Haematologica 93 : 1712-1717, 2008
 
15) Bain BJ : Leukemia Diagnosis, 4th ed, Wiley Blackwell, West Sussex, 2010, p55-56
 
16) Arber DA, Brunning RD, Le Beau MM et al : Acute myeloid leukaemia with recurrent genetic abnormalities. in Swerdlow SH, Campo E, Harris NL et al (eds) : "WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues", 4th ed, IARC Press, Lyon, 2008, pp110-123
 
17) Vardiman JW, Arber DA, Brunning RD et al : Therapy-related acute myeloid neoplasms. in Swerdlow SH, Campo E, Harris NL et al (eds) : "WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues", 4th ed, IARC Press, Lyon, 2008, pp127-129
 
18) Bain BJ : Leukaemia Diagnosis, 4th ed, Wiley Blackwell, West Sussex, 2010, pp158-160
 
19) Arber DA, Brunning RD, Orazi A et al : Acute myeloid leukaemia with myelodysplasia-related changes. in Swerdlow SH, Campo E, Harris NL et al (eds) : "WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues", 4th ed, IARC Press, Lyon, 2008, pp124-126
 
20) Arber DA, Brunning RD, Orazi A et al : Acute myeloid leukaemia with myelodysplasia-related changes. in Swerdlow SH, Campo E, Harris NL et al (eds) : "WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues", 4th ed, IARC Press, Lyon, 2008, pp138-139
 
21) Harris NL, Campo E, Jaffe ES et al : Introduction to the WHO classification of tumors of haematopoietic and lymphoid tissues. in Swerdlow SH, Campo E, Harris NL et al (eds) : "WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues", 4th ed, IARC Press, Lyon, 2008, pp14-15
 
P.179 掲載の参考文献
1) Pileri SA, Orazi A, Falini : Myeloid sarcoma. in Swerdlow SH, Campo E, Harris NL et al (eds) : "WHO Classification of Tumors of Haematopoietic and Lymphoid Tissue", 4th ed, IARC Press, Lyon, 2008, pp140-141
 
2) Pileri SA, Ascani S, Cox MC et al : Myeloid sarcoma : clinico-pathologic, phenotypic and cytogenetic analysis of 92 adult patients. Leukemia 21 : 340-350, 2007
PubMed
3) Abo-Yashima A, Satoh T, Abo T et al : Distinguishing between proliferating nodal lymphoid blasts in chronic myelogenous leukemia and non-Hodgkin lymphoma : Report of three cases and detection of a bcr/abl fusion signal by single cell analysis. Pathol Int 55 : 273-279, 2005
 
4) Arber DA, Brunning RD, LeBeau MM et al : Acute myeloid leukemia with recurrent genetic abnormalities. in Swerdlow SH, Campo E, Harris NL et al (eds) : "WHO Classification of Tumors of Haematopoietic and Lymphoid Tissue", 4th ed, IARC Press, Lyon, 2008, pp110-123
 
5) Tsunoda K, Satoh T, Akasaka K et al : Blastic plasmacytoid dendritic neoplasm : report of two cases. J Clin Exp Hematol 52 : 23-29, 2012
 
6) Hsieh PP, Olsen RJ, O'Malley DP et al : The role of Janus kinase 2V618F mutation in extramedullary hematopoiesis of the spleen in neoplastic myeloid disorders. Mod Pathol 20 : 929-935, 2007
PubMed
7) Randhawa J, Ostojic A, Vrhovac R et al : Splenomegaly in myelofibrosis-new options for therapy and the therapeutic potential of Janus kinase 2 inhibitors. J Hematol Oncol 5 : 43-49, 2012
PubMed
P.184 掲載の参考文献
1) Hitzler JK, Zipursky A : Origins of leukaemia in children with Down syndrome. Nat Rev Cancer 5 : 11-20, 2006
 
2) Zipursky A : Transient leukaemia-a benign form of leukaemia in newborn infants with trisomy 21. Br J Haematol 120 : 930-938, 2003
PubMed
3) 宮内潤, 泉二登志子 (編) : 骨髄疾患診断アトラス : 血球形態と骨髄病理. 中外医学社, 2010
 
4) Li Z, Godinho FJ, Klussmann JH et al : Developmental stage-selective effect of somatically mutated leukemogenic transcription factor GATA1. Nat Genet 37 : 613-619, 2005
 
5) Miyauchi J, Ito Y, Kawano T et al : Unusual diffuse liver fibrosis accompanying transient myeloproliferative disorder in Down's syndrome : a report of four autopsy cases and proposal of a hypothesis. Blood 80 : 1521-1527, 1992
PubMed
6) Wechsler J, Greene M, McDevitt MA et al : Acquired mutations in GATA1 in the megakaryoblastic leukemia of Down syndrome. Nat Genet 32 : 148-152, 2006
 
7) Ahmed M, Sternberg A, Hall G et al : Natural history of GATA1 mutations in Down syndrome. Blood 103 : 2480-2489, 2004
PubMed
8) Roy A, Roberts I, Norton A et al : Acute megakaryoblastic leukaemia (AMKL) and transient myeloproliferative disorder (TMD) in Down syndrome : a multi-step model of myeloid leukaemogenesis. Br J Haematol 147 : 3-12, 2009
PubMed
P.188 掲載の参考文献
1) Facchetti F, Jones DM, Petrella T : Blastic plasmacytoid dendritic cell neoplasm. in Swerdlow SH, Campo E, Harris NL et al (eds) : "WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues", 4th ed, IARC Press, Lyon, 2008, pp145-147
 
2) Bueno C, Almeida J, Lucio P et al : Incidence and characteristics of CD4+/HLA DRhi dendritic cell malignancies. Haematologica 89 : 58-69, 2004
PubMed
3) Dietrich S, Andrulis M, Hegenbart U et al : Blastic plasmacytoid dendritic cell neoplasia (BPDC) in elderly patients : results of a treatment algorithm employing allogeneic stem cell transplantation with moderately reduced conditioning intensity. Biol Blood Marrow Transplant 17 : 1250-1254, 2011
PubMed
4) Cota C, Vale E, Viana I et al : Cutaneous manifestations of blastic plasmacytoid dendritic cell neoplasm-morphologic and phenotypic variability in a series of 33 patients. Am J Surg Pathol 34 : 75-87, 2010
 
5) Jaye DL, Geigerman CM, Herling M et al : Expression of the plasmacytoid dendritic cell marker BDCA-2 supports a spectrum of maturation among CD4+ CD56+ hematodermic neoplasms. Mod Pathol 19 : 1555-1562, 2006
 
6) Garnache-Ottou F, Feuillard J, Ferrand C et al : Extended diagnostic criteria for plasmacytoid dendritic cell leukaemia. Br J Haematol 145 : 624-636, 2009
PubMed
7) Dijkman R, van Doorn R, Szuhai K et al : Gene-expression profiling and array-based CGH classify CD4+ CD56+ hematodermic neoplasm and cutaneous myelomonocytic leukemia as distinct disease entities. Blood 109 : 1720-1727, 2007
PubMed
8) Jardin F, Callanan M, Penther D et al : Recurrent genomic aberrations combined with deletions of various tumour suppressor genes may deregulate the G1/S transition in CD4+ CD56+ haematodermic neoplasms and contribute to the aggressiveness of the disease. Leukemia 23 : 698-707, 2009
 
9) Reimer P, Rudiger T, Kraemer D et al : What is CD4+ CD56+ malignancy and how should it be treated? Bone Marrow Transplant 32 : 637-646, 2003
PubMed
10) Jegalian AG, Buxbaum NP, Facchetti F et al : Blastic plasmacytoid dendritic cell neoplasm in children : diagnostic features and clinical implications. Haematologica 95 : 1873-1879, 2010
PubMed

第3部 鑑別ポイント

P.195 掲載の参考文献
1) Valent P, Horny HP, Bennett JM et al : Definitions and standards in the diagnosis and treatment of the myelodysplastic syndromes : Consensus statements and report from a working conference. Leuk Res 31 : 727-736, 2007
PubMed
2) Valent P, Horny HP : Minimal diagnostic criteria for myelodysplastic syndromes and separation from ICUS and IDUS : update and open questions. Eur J Clin Invest 39 : 548-553, 2009
PubMed
3) Wimazal F, Fonatsch C, Thalhammer R et al : Idiopathic cytopenia of undetermined significance (ICUS) versus low risk MDS : the diagnostic interface. Leuk Res 31 : 1461-1468, 2007
PubMed
4) Schroeder T, Ruf L, Bernhardt A et al : Distinguishing myelodysplastic syndromes (MDS) from idiopathic cytopenia of undetermined significance (ICUS) : HUMARA unravels clonality in a subgroup of patients. Ann Oncol 21 : 2267-2271, 2010
 
5) Hitzler JK, Zipursky A : Origins of leukaemia in children with Down syndrome. Nat Rev Cancer 5 : 11-20, 2005
PubMed
6) Roy A, Roberts I, Vyas P : Biology and management of transient abnormal myelopoiesis (TAM) in children with Down syndrome. Semin Fetal Neonatal Med 17 : 196-201, 2012
PubMed
7) Miyashita T, Asada M, Fujimoto J et al : Clonal analysis of transient myeloproliferative disorder in Down's syndrome. Leukemia 5 : 56-59, 1991
PubMed
8) Eguchi M, Ozawa T, Sakakibara H et al : Ultrastructural and ultracytochemical differences between megakaryoblastic leukemia in children and adults. Analysis of 49 patients. Cancer 70 : 451-458, 1992
PubMed
9) Massey GV, Zipursky A, Chang MN : A prospective study of the natural history of transient leukemia (TL) in neonates with Down syndrome (DS) : Children's Oncology Group (COG) study POG-9481. Blood 107 : 4606-4613, 2006
 
10) Leguit RJ, van den Tweel JG : The pathology of bone marrow failure. Histopathology 57 : 655-670, 2010
PubMed
11) Steensma DP : Dysplasia has a differential diagnosis : distinguishing genuine myelodysplastic syndromes (MDS) from mimics, imitators, copycats and impostors. Curr Hematol Malig Rep 7 : 310-320, 2012
 
12) Khalil F, Cualing H, Cogburn J et al : The criteria for bone marrow recovery post-myelosuppressive therapy for acute myelogenous leukemia : a quantitative study. Arch Pathol Lab Med 131 : 1281-1289, 2007
PubMed
13) Halfdanarson TR, Walker JA, Litzow MR et al : Severe vitamin B12 deficiency resulting in pancytopenia, splenomegaly and leukoerythroblastosis. Eur J Haematol 80 : 448-451, 2007
 
14) Leone G, Pagano L, Ben-Yehuda D et al : Therapy-related leukemia and myelodysplasia : susceptibility and incidence. Haematologica 92 : 1389-1398, 2007
PubMed
15) Godley LA, Larson RA : Therapy-related myeloid leukemia. Semin Oncol 35 : 418-429, 2008
PubMed
P.202 掲載の参考文献
1) Hartsock RJ, Smith EB, Petty CS : Normal variations with aging of the amount of hematopoietic tissue in bone marrow from the anterior iliac crest. a study made from 177 cases of sudden death examined by necropsy. Am J Clin Pathol 43 : 326-331, 1965
PubMed
2) Friebert SE, Shepardson LB, Shurin SB et al : Pediatric bone marrow cellularity : are we expecting too much? J Pediatr Hematol Oncol 20 : 439-443, 1998
 
3) 伊藤雅文 : 再生不良性貧血. 小澤敬也 (編) : 最新医学別冊 新しい診断と治療のABC 72, 最新医学社, 2011, pp31-38
 
4) Bohm J : Gelatinous transformation of the bone marrow : the spectrum of underlying diseases. Am J Surg Pathol 24 : 56-65, 2000
 
5) 伊藤雅文 : 薬剤性造血器障害 病理. 病理と臨床 27 : 733-739, 2009
Medical*Online
6) Choi JW, Fujino M, Ito M : F-blast is a useful marker for differentiating hypocellular refractory anemia from aplastic anemia. Int J Hematol 75 : 257-260, 2002
 
7) Nagai K, Kohno T, Chen Y et al : Diagnostic criteria for hypocellular acute leukemia : a clinical entity distinct from overt acute leukemia and myelodysplastic syndrome. Leukemia Res 20 : 563-574, 1996
PubMed
8) Osuji N, Beiske K, Randen U et al : Characteristic appearances of the bone marrow in T-cell large granular lymphocyte leukemia. Histopathology 50 : 547-554, 2007
 
9) Ito M, Kim J, Choi JW et al : Prevalence of Intravascular Large B-cell Lymphoma with Bone Marrow Involvement at Initial Presentation. Int J Hematol 77 : 159-163, 2003
 
10) 伊藤雅文 : 低形成骨髄. 病理形態学キーワード, 病理と臨床 28 (臨増) : 334-335, 2010
 
P.207 掲載の参考文献
1) Le Bousse-Kerdiles MC, MArtyre MC, Samson M : Cellular and molecular mechanisms underlying bone marrow and liver fibrosis : a review. Eur Cytokine Netw 19 : 69-80, 2008
 
2) Sramek J : Gelatinous transformation and other bone marrow stromal disorders : in Foucar K, Reichard KK, Wilson CS et al (eds) : "Diagnostic Pathology. Blood and Bone Marrow", Amirsys, Manitoba, 2012, pp26-29
 
3) Okamura T, Kinukawa N, Niho Y et al : Primary chronic myelofibrosis : clinical and prognostic evaluation in 336 Japanese patients. Int J Hematol 73 : 194-198, 2001
PubMed
4) Ricci C, Spinelli O, Salmoiraghi S et al : ASXL1 mutation s in primary and secondary myelofibrosis. Br J Haematol 156 : 404-407, 2012
 
5) Terreri A : Primary myelofibrosis : 2012 update on diagnosis, risk stratification, and management. Am J Hematol 86 : 1018-1026, 2011
 
P.213 掲載の参考文献
1) Thiele J, Kvasnicka HM, Diehl V : Initial (latent) polycythemia vera with thrombocytosis mimicking essential thrombocythemia. Acta Haematol 113 : 213-219, 2005
PubMed
2) Thiele J, Kvasnicka HM, Diehl V : Standardization of bone marrow features -does it work in hematopathology for histological discrimination of different disease patterns? Histol Histopathol 20 : 633-644, 2005
PubMed
3) Gianelli U, Iurlo A, Vener C et al : The significance of bone marrow biopsy and JAK2V617F mutation in the differential diagnosis between the "early" prepolycythemic phase of polycythemia vera and essential thrombocythemia. Am J Clin Pathol 130 : 336-342, 2008
PubMed
4) Thiele J, Kvasnicka HM, Mullauer L et al : Essential thrombocythemia versus early primary myelofibrosis : a multicenter study to validate the WHO classification. Blood 117 : 5710-5718, 2011
PubMed
5) Wilkins BS, Erber WN, Bareford B et al : Bone marrow pathology in essential thrombocythemia : interobserver reliability and utility for identifying disease subtypes. Blood 111 : 60-70, 2008
 
P.218 掲載の参考文献
1) 定平吉都, 藤原英世, 西村広健 : MDSの鑑別診断上問題となる病態・疾患. 病理と臨床 30 : 840-847, 2012
Medical*Online
2) 近藤敏範, 定平吉都, 杉原尚 : 骨髄増殖性腫瘍とJAK2遺伝子変異. 病理と臨床 27 : 1059-1065, 2009
Medical*Online
3) Vardiman JW, Porwit A, Brunning RD et al : Introduction and over view of the classification of the myeloid neoplasms. in Swerdlow SH, Campo E, Harris NL, et al (eds) : "WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues". IARC Press, Lyon, 2008, pp18-30
 
4) Wang SA, Hasserjian RP : Erythroid proliferations in myeloid neoplasms. Hum Pathol 43 : 153-164, 2012
PubMed
5) Liu W, Hasserjian RP, Hu Y et al : Pure erythroid leukemia : a reassessment of the entity using the 2008 World Health Organization classification. Mod Pathol 24 : 375-383, 2011
PubMed
6) 森将晏 : AML M6bの1例. 定平吉都 (編) : わかりやすい骨髄病理診断学-吸引クロット/生検組織の見方-. 西村書店, 2008, pp162-164
 
P.226 掲載の参考文献
1) Bain BJ, Clark DM : Lymphoproliferative disorders. in Wilkins BS (ed) : "Bone Marrow Pathology", Wiley-Blackwell, Oxford, 2010, pp300-420
 
2) Wilkins BS, Oscier D : Lymphoma. in Wickramasinghe SN, McCullough J (ed) : "Blood and Bone Marrow Pathology", Churchill Livingstone, Edinburgh, 2003, pp405-429
 
3) 石井源一郎, 張ヶ谷健一 : 悪性リンパ腫の骨髄浸潤の評価. 病理と臨床 19 : 1202-1221, 2001
 
4) 定平吉都 : 悪性リンパ腫の骨髄浸潤の診断手順. わかりやすい骨髄病理診断学, 西村書店, 2008, pp199-212
 
5) Isaacson PG, Chott A, Ott G et al : Enteropathy-associated T-cell lymphoma. Swerdlow SH, Campo E, Harris NL et al (ed) : "WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues", 4th ed, IARC Press, Lyon, 2008, pp289-291
 
6) Naemi K, Brynes RK, Reisian N et al : Benign lymphoid aggregates in the bone marrow : distribution patterns of B and T lymphocytes. Hum Pathol 44 : 512-520, 2013
 
7) Tripodo FV, Rizzo C, Stella A et al : Bone marrow biopsy in Hodgkin's lymphoma. Eur J Haematol 73 : 149-155, 2004
 
8) Daniel AA, Tracy IG : Bone marrow biopsy involvement by non-Hodgkin's lymphoma frequency of lymphoma types, patterns, blood involvement, and discordance with other sites in 450 specimens. Am J Surg Pathol 29 : 1549-1557, 2005
 
9) Kent SA, Variakojis D, Peterson LC : Comparative study of marginal zone lymphoma involving bone marrow. Am J Clin Pathol 117 : 698-708, 2002
PubMed
10) Guilloton F, Caron G, Menard C et al : Mesenchymal stromal cells orchestrate follicular lymphoma cells niche through the CCL2-dependent recruitment and polarization of monocytes. Blood 119 : 2556-2567, 2012
PubMed
11) Murase T, Yamaguchi M, Suzuki R et al : Intravascular large B cell lymphoma (IVLBCL). Blood 109 : 478-485, 2007
 
12) Martinez A, Ponzoni M, Agastinelli C et al : Primary bone marrow lymphoma : An uncommon extranodal presentation of aggressive non-Hodgkin lymphomas. Am J Surg Pathol 36 : 296-304, 2012
 
13) Osuji N, Beiske K, Randen U et al : Characteristic appearances of the bone marrow in T-cell large granular lymphocyte leukaemia. Histopathology 50 : 547-554, 2007
 
14) Young KH, Zhang D, Malik JT et al : Fulminant EBV-driven CD8 T-cell lymphoproliferative disorder following primary acute EBV infection : A unique spectrum of T-cell malignancy. Int J Clin Exp Pathol 1 : 185-197, 2008
PubMed
15) Dogan A, Morice W : Bone marrow histopathology in peripheral T-cell lymphomas. Br J Haematol 127 : 140-154, 2004
PubMed
16) Weinberg OK, Seo K, Arber DA : Prevalence of bone marrow involvement in systemic anaplastic large cell lymphoma. Hum Pathol 39 : 1331-1340, 2008
PubMed
17) Damm-Welk C, Busch K, Burkhardt B et al : Prognostic significance of circulating tumor cells in bone marrow or peripheral blood as detected by qualitative and quantitative PCR in pediatric NPM-ALK-positive anaplastic large cell lymphoma. Blood 110 : 670-677, 2007
PubMed
P.237 掲載の参考文献
1) 定平吉都 : 骨髄組織標本の免疫染色. 定平吉都 (編) : わかりやすい骨髄病理診断学-吸引クロット, 生検組織の見方-, 西村書店, 2008, pp27-41
 
2) Vardiman JW, Porwit A, Brunning RD et al : Introduction and over view of the classification of the myeloid neoplasms. in Swerdlow SH, Campo E, Harris NL et al (eds) : "WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues", IARC Press, Lyon, 2008, pp18-30
 
3) 秋山隆, 定平吉都 : 各臓器, 疾患で用いられる抗体とその応用 : 骨髄. 病理と臨床 25 (臨増) : 170-176, 2007
 
4) Sadahira Y, Kanzaki A, Wada H et al : Immunohistochemical identification of erythroid precursors in paraffin embedded bone marrow sections : spectrin is a superior marker to glycophorin. J Clin Pathol 52 : 919-921, 1999
PubMed
5) Choi JW, Fujino M, Ito M : F-blast is a useful marker for differentiating hypocellular refractory anemia from aplastic anemia. Int J Hematol 75 : 257-260, 2002
 
6) Raess PW, Paessler ME, Bagg A et al : α-Hemoglobinstabilizing protein is a sensitive and specific marker of erythroid precursors. Am J Surg Pathol 36 : 1538-1547, 2012
 
7) Dunphy CH : Applications of flow cytometry and immunohistochemistry to diagnostic hematopathology. Arch Pathol Lab Med 128 : 1004-1022, 2004
PubMed
8) Hoyer JD, Grogg KL, Hanson CA et al : CD33 detection by immunohistochemistry in paraffin-embedded tissues. Am J Clin Pathol 129 : 316-323, 2008
PubMed
9) Akiyama T, Sadahira Y, Matsubara K et al : Immunohistochemical detection of sphingosine-1-phosphate receptor 1 in vascular and lymphatic endothelial cells. J Mol Histol 39 : 527-533, 2008
PubMed
10) Falini B, Mecucci C, Tiacci E et al : Cytoplasmic nucleophosmin in acute myelogenous leukemia with a normal karyotype. N Engl J Med 352 : 254-266, 2005
PubMed
11) Gruszka AM, Lavorgna S, Consalvo MI et al : A monoclonal antibody against mutated nucleophosmin 1 for the molecular diagnosis of acute myeloid leukemias. Blood 116 : 2096-2102, 2010
PubMed
12) 定平吉都 : MDS (骨髄異形成症候群) の病理組織像. 臨床検査 56 : 1349-1354, 2012
 
13) Falini B, Flenghi L, Fagioli M et al : Immunocytochemical diagnosis of acute promyelocytic leukemia (M3) with the monoclonal antibody PG-M3 (anti-PML). Blood 90 : 4046-4053, 1997
PubMed
14) Zhao W, Claxton DF, Medeiros LJ et al : Immunohistochemical analysis of CBFbeta-SMMHC protein reveals a unique nuclear localization in acute myeloid leukemia with inv (16) (p13q22). Am J Surg Pathol 30 : 1436-1444, 2006
PubMed
15) Byers R, Hornick JL, Tholouli E et al : Detection of IDH1 R132H mutation in acute myeloid leukemia by mutationspecific immunohistochemistry. Appl Immunohistochem Mol Morphol 20 : 37-40, 2012
PubMed
16) Garnache-Ottou F, Feuillard J, Ferrand C et al : Extended diagnostic criteria for plasmacytoid dendritic cell leukaemia. Br J Haematol 145 : 624-636, 2009
PubMed
17) Horny HP, Sotlar K, Stellmacher F et al : The tryptase positive compact round cell infiltrate of the bone marrow (TROCI-BM) : a novel histopathological finding requiring the application of lineage specific markers. J Clin Pathol 59 : 298-302, 2006
PubMed

第4部 臨床との連携

P.248 掲載の参考文献
1) 日本血液学会・日本リンパ網内系学会 (編) : 悪性リンパ腫・効果判定基準. 造血器腫瘍取扱い規約, 金原出版, 2010, pp141-149
 
2) 定平吉都 (編) : 悪性リンパ腫の骨髄浸潤の評価. わかりやすい骨髄病理診断学, 西村書店, 2008, pp190-198
 
3) Lin C, Luciani A, Itti E et al : Whole-body diffusion-weighted magnetic resonance imaging with apparent diffuse large B-cell lymphoma. Eur Radiol 20 : 2027-2038, 2010
PubMed
4) Cheson BD, Pfistner B, Juweid ME et al : Revised response criteria for malignant lymphoma. J Clin Oncol 25 : 579-586, 2007
PubMed
5) Raanani P, Shasha Y, Perry C et al : Is CT scan still necessary for staging in Hodgkin and non-Hodgkin lymphoma patients in the PET/CT era? Ann Oncol 17 : 117-122, 2006
PubMed
6) Cheson BD, Horning SJ, Coiffier B et al : Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group. J Clin Oncol 17 : 1244-1253, 1999
 
7) Juweid ME, Wiseman GA, Vose JM et al : Response assessment of aggressive non-Hodgkin's lymphoma by integrated International Workshop Criteria and fluorine-18-fluorodeoxyglucose positron emission tomography. J Clin Oncol 23 : 4652-4661, 2005
PubMed
8) Hutchings M, Mikhaeel NG, Fields PA et al : Prognostic value of interim FDG-PET after two or three cycles of chemotherapy in Hodgkin lymphoma. Ann Oncol 16 : 1160-1168, 2005
 
9) Haioun C, Itti E, Rahmouni A et al : [18F] fluoro-2-deoxy-D-glucose positron emission tomography (FDG-PET) in aggressive lymphoma : an early prognostic tool for predicting patient outcome. Blood 106 : 1376-1381, 2005
PubMed
10) Durie BGM, Salmon SE : A clinical staging system for multiple myeloma. Cancer 36 : 842-854, 1975
 
11) Dimopoulos M, Terpos E, Comenzo RL et al : International myeloma working group consensus statement and guidelines regarding the current role of imaging techniques in the diagnosis and monitoring of multiple myeloma. Leukemia 23 : 1545-1556, 2009
 
12) Bellaiche L, Laredo JD, Liote F et al : Magnetic resonance appearance of monoclonal gammopathies of unknown significance and multiple myeloma. The GRI Study Group. Spine 22 : 2551-2557, 1997
 
13) Vande Berg BC, Michaux L, Lecouvet FE et al : Nonmyelomatous monoclonal gammopathy : correlation of bone marrow MR images with laboratory findings and spontaneous clinical outcome. Radiology 202 : 247-251, 1997
PubMed
14) Hillner BE, Siegel BA, Shields AF et al : Relationship between cancer type and impact of PET and PET/CT on intended management : findings of the mational oncologic PET registry. J Nucl Med 49 : 1928-1935, 2008
 
15) Bartel TB, Haessler J, Brown TL et al : F18-fluorodeoxyglucose positron emission tomography in the context of other imaging techniques and prognostic factors in multiple myeloma. Blood 114 : 2068-2076, 2009
PubMed
16) Durie BGM : The role of anatomic and functional staging in myeloma : description of Durie/Salmon plus staging system. Eru J Cancer 42 : 1539-1543, 2006
 
P.252 掲載の参考文献
1) Bennett JM, Catovsky D, Daniel MT et al : Proposals for the classification of the myelodysplastic syndromes. Br J Haematol 51 : 189-199, 1982
PubMed
2) Greenberg P, Cox C, LeBeau MM et al : International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood 89 : 2079-2088, 1997
PubMed
3) Brunning RD, Bennet JM, Flandrin G et al : Myelodysplastic syndromes. in Jaffe ES, Harris NL, Stein H et al (eds) : "WHO Classification of Tumours. Pathology & Genetics. Tumours of Haematopoietic and Lymphoid Tissues", IARC Press, Lyon, 2001, pp61-73
 
4) Malcovati L, Porta MG, Pascutto C et al : Prognostic factors and life expectancy in myelodysplastic syndromes classified according to WHO criteria : a basis for clinical decision making. J Clin Oncol 23 : 7594-7603, 2005
PubMed
5) Brunning RD, Orazi A, Germing U et al : Myelodysplastic syndromes. in Swerdlow SH, Campo E, Harris NL et al (eds) : "WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues", IARC Press, Lyon, 2008, pp87-107
 
6) National Comprehensive Cancer Network : NCCN Clinical Practice Guidelines in Oncology. Myelodysplastic syndromes. Version 2, 2013 (http://www.nccn.org/professionals/physician_gls/f_guidelines.asp)
 
7) Greenberg PL, Tuechler H, Schanz J et al : Revised international prognostic scoring system for myelodysplastic syndromes. Blood 120 : 2454-2465, 2012
PubMed
P.259 掲載の参考文献
1) Slovak ML, Kopecky KJ, Cassileth PA et al : Karyotypic analysis predicts outcome of preremission and postremission therapy in adult acute myeloid leukemia : a Southwest Oncology Group/Eastern Cooperative Oncology Group Study. Blood 96 : 4075-4083, 2000
 
2) Grimwade D, Walker H, Oliver F et al : The importance of diagnostic cytogenetics on outcome in AML : analysis of 1,612 patients entered into the MRC AML 10 trial. The Medical Research Council Adult and Children's Leukaemia Working Parties. Blood 92 : 2322-2333, 1998
 
3) O'Donnell MR, Abboud CN, Altman J et al : Acute myeloid leukemia. J Natl Compr Canc Netw 10 : 984-1021, 2012
PubMed
4) Grimwade D, Walker H, Harrison G et al : Medical Research Council Adult Leukemia Working Party. The predictive value of hierarchical cytogenetic classification in older adults with acute myeloid leukemia (AML) : analysis of 1065 patients entered into the United Kingdom Medical Research Council AML11 trial. Blood 98 : 1312-1320, 2001
PubMed
5) 栗山一孝, 吉田真一郎, 今西大介他 : JALSGにおけるAMLの化学療法-スコアリングシステムを用いた予後判定-. 臨床血液 39 : 98-102, 1998
 
6) Schlenk RF, Benner A, Krauter J et al : Individual patient data-based meta-analysis of patients aged 16 to 60 years with core binding factor acute myeloid leukemia : a survey of the German Acute Myeloid Leukemia Intergroup. J Clin Oncol 22 : 3741-3750, 2004
PubMed
7) Marchesi F, Annibali O, Cerchiara E et al : Cytogenetic abnormalities in adult non-promyelocytic acute myeloid leukemia : a concise review. Crit Rev Oncol Hematol 80 : 331-346, 2011
PubMed
8) Schaich M, Schlenk RF, Al-Ali HK et al : Prognosis of acute myeloid leukemia patients up to 60 years of age exhibiting trisomy 8 within a non-complex karyotype : individual patient data-based meta-analysis of the German Acute Myeloid Leukemia Intergroup. Haematologica 92 : 763-770, 2007
PubMed
9) Testoni N, Borsaru G, Martinelli G et al : 3q21 and 3q26 cytogenetic abnormalities in acute myeloblastic leukemia : biological and clinical features. Haematologica 84 : 690-694, 1999
PubMed
10) Woo KS, Kim KE, Kim KH et al : Deletions of chromosome arms 7p and 7q in adult acute myeloid leukemia : a marker chromosome confirmed by array comparative genomic hybridization. Cancer Genet Cytogenet 194 : 71-74, 2009
PubMed
11) Ernst T, Chase AJ, Score J et al : Inactivating mutations of the histone methyltransferase gene EZH2 in myeloid disorders. Nat Genet 42 : 722-726, 2010
PubMed
P.268 掲載の参考文献
1) Feugier P, Van Hoof A, Sebban C et al : Long-term results of the R-CHOP study in the treatment of elderly patients with dif fuse large B-cell lymphoma : a study by the Groupe d'Etude des Lymphomes de l'Adulte. J Clin Oncol 23 : 4117-4126, 2005
 
2) Hiraga J, Tomita A, Sugimoto T et al : Down-regulation of CD20 expression in B-cell lymphoma cells after treatment with rituximab-containing combination chemotherapies : its prevalence and clinical significance. Blood 113 : 4885-4893, 2009
 
3) Ito M, Kim J, Choi JW et al : Prevalence of Intravascular Large B-cell Lymphoma with Bone Marrow Involvement at Initial Presentation. Int J Hematol 77 : 159-163, 2003
 
4) Ishida T, Ueda R : CCR4 as a novel molecular target for immunotherapy of cancer. Cancer Sci 97 : 1139-1146, 2006
PubMed
5) Buccisano F, Maurillo L, Del Principe MI et al : Prognostic and therapeutic implications of minimal residual disease detection in acute myeloid leukemia. Blood 119 : 332-341, 2012
PubMed
6) Tallman MS, Anderson JW, Schiffer CA et al : All-transretinoic acid in acute promyelocytic leukemia. N Engl J Med 337 : 1021-1028, 1997
 
7) Thiele J, Kvasnicka HM, Schmitt-Graeff A et al : Effects of the tyrosine kinase inhibitor imatinib mesylate (STI571) on bone marrow features in patients with chronic myelogenous leukemia. Histol Histopathol 19 : 1277-1288, 2004
 
P.273 掲載の参考文献
1) Ward JF : DNA damage produced by ionizing radiation in mammalian cells : identities, mechanisms of formation, and repairability. Prog Nucl Acid Res Mol Biol 35 : 95-125, 1988
 
2) Hall EJ, Giaccia AJ (eds) : Radiobiology for the Radiologist, 6th ed, Lippincott Williams & Wilkins, Philadelphia, 2006
 
3) Beckman KD, Ames BN : The free radical theory of aging matures. Physiol Rev 78 : 547-581, 1998
 
4) Pollycove M, Feinendegen LE : Radiation-induced versus endogenous DNA damage : possible effect of inducible protective responses in mitigating endogenous damage. Hum Exp Toxical 22 : 290-306, 2003
 
5) Jeggo PA : Risks from low dose/dose rate radiation : what an understanding of DNA damage response mechanisms can tell us. Heath Phys 97 : 416-425, 2009
 
6) Mullenders L, Atkinson M, Paretzke H et al : Assessing cancer risks of low-dose radiation. Nat Rev Cancer 9 : 596-604, 2009
PubMed
7) Rothkamm K, Lobrich M : Evidence for a lack of DNA double-strand break repair in human cells exposed to very low x-ray doses. Proc Natl Acad Sci USA 100 : 5057-5062, 2003
 
8) Bonner WM, Rondon CE, Dickey JS et al : GammaH2AX and cancer. Nat Rev Cancer 8 : 957-967, 2008
 
9) Matsuo T, Tomonaga M, Bennett JM et al : Reclassification of leukemia among A-bomb survivors in Nagasaki using French-American-British (FAB) classification for acute leukemia. Jpn J Clin Oncol 18 : 91-96, 1988
PubMed
10) Tomonaga M, Matsuo T, Carter RL et al : Differential effects of atomic bomb irradiation in inducing major leukemia types : analyses of open-city cases including the Life Span Study cohort based upon update diagnostic systems and the dosimetry system 1986 (DS86). RERF TR 9-91 : 1-26, 1993
 
11) Preston DL, Kusumi S, Tomonaga M et al : Cancer incidence in atomic-bomb survivors. Part III. Leukemia, lymphoma and multiple myeloma, 1950-1987. Radiat Res 137 : S68-S97, 1994
PubMed
12) Richardson D, Sugiyama H, Nishi N et al : Ionizing radiation and leukemia mortality among Japanese Atomic Bomb Survivors, 1950-2000. Radiat Res 172 : 368-382, 2009
PubMed
13) Iwanaga M, Hsu WL, Soda M et al : Risk of myelodysplastic syndromes in people exposed to ionizing radiation : a retrospective cohort study of Nagasaki atomic bomb survivors. J Clin Oncol 29 : 428-434, 2011
PubMed
14) Iwanaga M, Tagawa M, Tsukasaki K et al : Relationship between monoclonal gammopathy of undetermined significance and radiation exposure in Nagasaki atomic bomb survivors. Blood 113 : 1639-1650, 2009
PubMed
P.279 掲載の参考文献
1) Vardiman JW, Porwit A, Brunning RD et al : Introduction and over view of the classification of the myeloid neoplasms. in Swerdlow SH, Campo E, Harris NL et al (eds) : "WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues", IARC Press, Lyon, 2008, pp18-30
 
2) Lee SH, Erber WN, Porwit A et al : International council for standardization in hematology. ICSH guidelines for the standardization of bone marrow specimens and reports. Int J Lab Hematol 30 : 349-364, 2008
 
3) 荒関かやの, 松田晃, 通山薫他 : 本邦における骨髄不全症候群診断のための検査に関する実態調査. 厚生労働科学研究費補助金難治性疾患克服研究事業特発性造血障害に関する調査研究班. 臨床血液 53 : 691-697, 2012
 
4) Thiele J, Kvasnicka HM, Facchetti F et al : European consensus on grading bone marrow fibrosis and assessment of cellularity. Haematologica 90 : 1128-1132, 2005
PubMed
5) 定平吉都 : 骨髄組織標本の免疫染色. 定平吉都 (編) : わかりやすい骨髄病理診断学-吸引クロット, 生検組織の見方-, 西村書店, 2008, pp27-41
 

書評

最近チェックした商品履歴

Loading...